Hashimoto, K.; Kaira, K.; Yamaguchi, O.; Mouri, A.; Shiono, A.; Miura, Y.; Murayama, Y.; Kobayashi, K.; Kagamu, H.; Kuji, I.
Potential of FDG-PET as Prognostic Significance after anti-PD-1 Antibody against Patients with Previously Treated Non-Small Cell Lung Cancer. J. Clin. Med. 2020, 9, 725.
https://doi.org/10.3390/jcm9030725
AMA Style
Hashimoto K, Kaira K, Yamaguchi O, Mouri A, Shiono A, Miura Y, Murayama Y, Kobayashi K, Kagamu H, Kuji I.
Potential of FDG-PET as Prognostic Significance after anti-PD-1 Antibody against Patients with Previously Treated Non-Small Cell Lung Cancer. Journal of Clinical Medicine. 2020; 9(3):725.
https://doi.org/10.3390/jcm9030725
Chicago/Turabian Style
Hashimoto, Kosuke, Kyoichi Kaira, Ou Yamaguchi, Atsuto Mouri, Ayako Shiono, Yu Miura, Yoshitake Murayama, Kunihiko Kobayashi, Hiroshi Kagamu, and Ichiei Kuji.
2020. "Potential of FDG-PET as Prognostic Significance after anti-PD-1 Antibody against Patients with Previously Treated Non-Small Cell Lung Cancer" Journal of Clinical Medicine 9, no. 3: 725.
https://doi.org/10.3390/jcm9030725
APA Style
Hashimoto, K., Kaira, K., Yamaguchi, O., Mouri, A., Shiono, A., Miura, Y., Murayama, Y., Kobayashi, K., Kagamu, H., & Kuji, I.
(2020). Potential of FDG-PET as Prognostic Significance after anti-PD-1 Antibody against Patients with Previously Treated Non-Small Cell Lung Cancer. Journal of Clinical Medicine, 9(3), 725.
https://doi.org/10.3390/jcm9030725